For O
people B-acr
who O
cannot O
tolerate B-acn
aminosalicylates B-obj
, O
consider B-acn
a O
time-limited B-mod
course B-obj
of O
a O
topical B-mod
or O
an O
oral B-mod
corticosteroid B-obj
. O

Maintain B-acn
blood B-obj
pressure I-obj
below B-mod
130/80 I-mod
mmHg I-mod
for O
people B-acr
with O
advanced B-mod
pancreatic B-obj
cancer I-obj
. O

Consider B-acn
adjuvant B-mod
therapy B-obj
after O
surgery B-obj
for O
people B-acn
with O
invasive B-mod
breast B-obj
cancer I-obj
, O
and O
ensure B-acn
that O
recommendations B-obj
are O
recorded B-mod
at O
the O
multidisciplinary B-mod
team B-obj
meeting I-obj
. O

Request B-acn
the O
oestrogen B-obj
receptor I-obj
, O
progesterone B-obj
receptor I-obj
and O
human B-obj
epidermal I-obj
growth I-obj
receptor I-obj
2 I-obj
status I-obj
of O
all O
invasive B-mod
breast B-obj
cancers I-obj
simultaneously B-mod
at O
the O
time O
of O
initial B-mod
histopathological B-obj
diagnosis I-obj
. O

Where O
appropriate O
, O
functional B-obj
tests I-obj
, O
including O
the O
exercise B-obj
tolerance I-obj
test I-obj
, O
should O
be O
considered B-mod
to O
aid B-acn
in O
the O
risk B-obj
stratification I-obj
of O
patients B-acr
with O
known B-mod
CAD B-obj
. O

When O
peripheral B-mod
SpA B-obj
is O
suspected B-mod
, O
US B-obj
or O
MRI B-obj
may O
be O
used B-mod
to O
detect B-acn
peripheral B-mod
enthesitis B-obj
, O
which O
may O
support B-acn
the O
diagnosis B-obj
of O
SpA B-obj
. O

Low B-mod
dose I-mod
pegylated B-obj
IFN I-obj
maintenance I-obj
monotherapy I-obj
should O
not O
be O
used B-mod
in O
patients B-acr
with O
compensated B-mod
cirrhosis B-obj
. O

Offer B-acn
radiotherapy B-obj
using B-acn
40 B-obj
Gy I-obj
in O
15 O
fractions O
with O
concomitant B-obj
and O
up O
to O
12 O
cycles O
of O
adjuvant B-mod
temozolomide B-obj
for O
people B-acr
aged O
around B-mod
70 B-obj
or O
over B-mod
. O

Amiodarone B-obj
may O
be O
used B-mod
when O
prophylaxis B-obj
for O
atrial B-obj
fibrillation I-obj
and O
ventricular B-obj
arrhythmias I-obj
is O
indicated B-mod
following B-acn
CABG B-obj
surgery I-obj
. O

Offer B-acn
immediate O
enteral B-mod
or O
parenteral B-mod
nutrition B-obj
after O
surgery O
to O
people B-acr
who O
are O
having B-acn
radical B-obj
surgery I-obj
for O
oesophageal B-obj
and O
gastro-oesophageal B-mod
junctional I-mod
cancers B-mod
. O

If O
the O
person B-acr
is O
aged O
under B-mod
80 B-obj
years I-obj
with O
stage B-obj
1 I-obj
hypertension I-obj
and O
has B-acn
target B-obj
organ I-obj
damage I-obj
, O
offer B-acn
antihypertensive B-mod
drug B-obj
treatment I-obj
. O

If O
a O
woman B-acr
is O
pregnant B-mod
, O
offer B-acn
ultrasound B-obj
instead O
of O
CT B-obj
. O

MRI B-obj
of O
the O
SI B-obj
joints I-obj
and/or O
the O
spine B-obj
may O
be O
used B-mod
to O
assess B-acn
and O
monitor B-acn
disease B-obj
activity I-obj
in O
axial B-mod
SpA B-obj
, O
providing B-acn
additional B-mod
information B-obj
on O
top O
of O
clinical B-mod
and O
biochemical B-mod
assessments B-obj
. O

If O
the O
person B-acr
is O
with O
CKD B-obj
and O
diabetes B-obj
and O
an O
ACR B-obj
of O
3 B-mod
mg/mmol I-mod
or O
more B-mod
, O
offer B-acn
a O
low-cost B-mod
renin-angiotensin-aldosterone I-mod
system B-obj
antagonist I-obj
. O

Use B-acn
nasal B-obj
cannula I-obj
or O
incubator B-obj
oxygen I-obj
for O
preterm B-mod
babies B-acr
who O
need B-acn
supplemental B-mod
oxygen B-obj
. O

Do O
not O
offer B-acn
azathioprine B-obj
, O
mercaptopurine B-obj
or O
methotrexate B-obj
as O
monotherapy B-obj
to O
induce B-acn
remission B-obj
. O

In O
patients B-acr
with O
peripheral B-mod
arthritis B-obj
and O
an O
inadequate B-mod
response B-obj
to O
at O
least O
one O
csDMARD B-obj
, O
in O
whom O
TNF B-obj
inhibitors I-obj
are O
not O
appropriate B-mod
, O
bDMARDs B-obj
targeting I-obj
IL12/23 I-obj
or O
IL17 B-obj
pathways I-obj
may O
be O
considered B-mod
. O

Treatment B-obj
should O
be O
aimed B-mod
at O
reaching B-acn
the O
target B-obj
of O
remission B-obj
or O
, O
alternatively O
, O
minimal/low B-mod
disease B-obj
activity I-obj
, O
by O
regular B-mod
monitoring B-obj
and O
appropriate B-mod
adjustment B-obj
of O
therapy B-obj
. O

For O
preterm B-mod
babies B-acr
who O
need B-acn
invasive B-mod
ventilation B-obj
, O
use B-acn
volume-targeted B-mod
ventilation B-obj
in O
combination O
with O
synchronised B-mod
ventilation B-obj
as O
the O
primary B-mod
mode B-obj
of O
respiratory B-mod
support B-obj
. O

Consider B-acn
prostaglandin B-obj
E1 I-obj
as O
an O
option O
for O
treating B-acn
postpartum B-obj
haemorrhage I-obj
in O
women B-acr
with O
asthma B-mod
because O
there O
is O
no O
evidence O
it B-acr
worsens B-acn
asthma B-obj
. O

CVD B-obj
risk I-obj
estimation I-obj
for O
patients B-acr
with O
RA B-obj
, O
AS B-obj
or O
PsA B-obj
should O
be O
performed B-mod
according O
to O
national B-obj
guidelines I-obj
and O
the O
SCORE B-obj
CVD I-obj
risk I-obj
prediction I-obj
model I-obj
should O
be O
used B-mod
if O
no O
national B-obj
guideline I-obj
is O
available B-mod
. O

Women B-acr
with O
platinum B-mod
resistant I-mod
relapsed B-obj
ovarian I-obj
cancer I-obj
should O
be O
offered B-mod
bevacizumab B-obj
in O
combination O
with O
paclitaxel B-obj
. O

For O
eligible B-mod
people B-obj
with O
stage B-obj
3B I-obj
NSCLC I-obj
who O
cannot O
tolerate B-acn
or O
who O
decline B-acn
chemoradiotherapy B-obj
, O
consider B-acn
radical B-mod
radiotherapy B-obj
. O

MRI B-obj
may O
also O
be O
used B-mod
to O
predict B-acn
development B-obj
of O
new B-mod
radiographic B-obj
syndesmophytes I-obj
. O

If O
conventional B-mod
radiography B-obj
is O
negative B-mod
, O
CT B-obj
should O
be O
performed B-mod
. O

In O
patients B-acr
with O
syndesmophytes B-obj
in O
the O
lumbar B-obj
spine I-obj
on O
conventional B-mod
radiography B-obj
, O
osteoporosis B-obj
should O
be O
assessed B-mod
by O
hip B-obj
DXA I-obj
, O
supplemented B-obj
by O
either O
spine B-obj
DXA I-obj
in O
lateral B-mod
projection B-obj
or O
possibly O
QCT B-obj
of O
the O
spine B-obj
. O

If O
a O
patient B-acr
is O
in O
persistent B-mod
remission B-obj
after O
having B-acn
tapered B-mod
GC B-obj
, O
one O
can O
consider B-acn
tapering B-mod
bDMARDs B-obj
, O
especially O
if O
this O
treatment B-obj
is O
combined B-mod
with O
a O
csDMARD B-obj
. O

Systemic B-mod
glucocorticoids B-obj
may O
be O
used B-mod
with O
caution O
at O
the O
lowest B-mod
effective I-mod
dose B-obj
. O

If O
the O
person B-acr
is O
aged O
under B-mod
80 I-obj
years O
with O
stage B-obj
1 I-obj
hypertension I-obj
and O
has B-acn
established B-mod
cardiovascular B-obj
disease I-obj
, O
offer B-acn
antihypertensive B-mod
drug B-obj
treatment I-obj
. O

Do O
not O
offer B-acn
cinacalcet B-obj
to O
pregnant B-mod
women B-acr
with O
primary B-mod
hyperparathyroidism B-obj
. O

Prescribe B-acn
metformin B-obj
with O
caution O
for O
those O
at O
risk O
of O
a O
sudden B-mod
deterioration I-mod
in O
kidney B-obj
function I-obj
and O
those O
at O
risk O
of O
eGFR B-obj
falling I-obj
below B-mod
45 I-mod
ml/minute/1.73m2 I-mod
. O

If O
dipstick B-obj
screening I-obj
is O
positive B-mod
, O
use B-acn
albumin:creatinine B-obj
ratio I-obj
or O
protein:creatinine B-obj
ratio I-obj
to O
quantify B-acn
proteinuria B-obj
in O
pregnant B-mod
women B-obj
. O

In O
patients B-acr
with O
peripheral B-mod
arthritis B-obj
, O
particularly O
in O
those O
with O
many O
swollen B-mod
joints B-obj
, O
structural B-mod
damage B-obj
in O
the O
presence O
of O
inflammation B-obj
, O
high B-mod
ESR/CRP B-obj
and/or O
clinically B-mod
relevant I-mod
extra-articular B-obj
manifestations I-obj
, O
csDMARDs B-obj
should O
be O
considered B-mod
at O
an O
early B-mod
stage B-obj
, O
with O
methotrexate B-obj
preferred O
in O
those O
with O
relevant B-mod
skin B-obj
involvement I-obj
. O

Monitor B-acn
the O
effects B-obj
of O
azathioprine B-obj
, O
mercaptopurine B-obj
and O
methotrexate B-obj
as O
advised B-mod
in O
the O
British B-obj
National I-obj
Formulary I-obj
or O
British B-obj
National I-obj
Formulary I-obj
for I-obj
Children I-obj
. O

In O
patients B-acr
with O
suspected B-mod
stable B-obj
angina I-obj
, O
the O
exercise B-obj
tolerance I-obj
test I-obj
should O
not O
be O
used B-mod
routinely O
as O
a O
first B-mod
line I-mod
diagnostic B-obj
tool I-obj
. O

In O
patients B-acr
with O
stable B-mod
angina B-obj
requiring O
percutaneous B-mod
coronary B-obj
intervention I-obj
for O
in O
stent B-obj
restenosis I-obj
, O
a O
drug B-obj
eluting I-obj
balloon I-obj
or O
a O
second B-mod
or O
third B-mod
generation I-mod
drug B-obj
eluting I-obj
stent I-obj
should O
be O
considered B-mod
. O

Consider B-acn
a O
maintenance B-obj
dosage I-obj
higher O
than O
20 O
mg/kg O
daily O
if O
therapeutic B-mod
efficacy B-obj
is O
not O
achieved B-mod
, O
while O
ensuring B-acn
that O
a O
safe B-mod
plasma B-obj
level I-obj
is O
maintained B-mod
. O

Patients B-acr
with O
heart B-obj
failure I-obj
with O
reduced B-mod
ejection B-obj
fraction I-obj
of O
all O
NYHA B-obj
functional I-obj
classes I-obj
, O
should O
be O
given B-mod
angiotensin B-mod
converting I-mod
enzyme B-obj
inhibitors I-obj
. O

Before O
starting B-acn
medium/high-dose B-mod
GC B-obj
treatment I-obj
, O
consider B-acn
comorbidities B-obj
predisposing I-obj
to O
AEs B-obj
. O

Patients B-acr
with O
CHC B-obj
who O
are O
on O
a O
drug B-obj
treatment I-obj
programme I-obj
should O
be O
considered B-mod
for O
treatment B-obj
. O

Digoxin B-obj
should O
not O
be O
used B-mod
for O
prophylaxis B-obj
of O
atrial B-obj
fibrillation I-obj
following B-acn
CABG B-obj
surgery I-obj
. O

Patients B-acr
with O
larger B-mod
tumours B-obj
may O
be O
considered B-mod
for O
oncoplastic B-obj
surgery I-obj
instead O
of O
mastectomy B-obj
. O

Consider B-acn
prostaglandin B-obj
E1 I-obj
or O
prostaglandin B-obj
E2 I-obj
as O
options O
for O
inducing B-acn
labour B-obj
in O
women B-acr
with O
asthma B-obj
because O
there O
is O
no O
evidence O
that O
they B-acr
worsen B-acn
asthma B-obj
. O

The O
decision B-obj
on O
when O
to O
repeat B-acn
MRI B-obj
depends B-acn
on O
the O
clinical B-mod
circumstances B-obj
. O

Maintain B-acn
a O
blood B-obj
glucose I-obj
concentration I-obj
between O
4 O
and O
11 O
mmol/litre O
in O
people B-acr
with O
acute B-mod
stroke B-obj
. O

Combination B-obj
intravenous I-obj
SACT I-obj
should O
be O
considered B-mod
for O
patients B-acr
with O
SCLC B-obj
over O
70 O
years O
of O
age O
with O
performance B-obj
status I-obj
0-2 I-obj
. O

Consider B-acn
ovarian B-obj
function I-obj
suppression I-obj
in O
addition O
to O
endocrine B-obj
therapy I-obj
for O
premenopausal B-mod
women B-obj
with O
ER-positive B-mod
invasive I-mod
breast B-obj
cancer I-obj
. O

If O
the O
person B-acr
is O
aged O
under B-mod
80 B-obj
years I-obj
with O
stage B-obj
1 I-obj
hypertension I-obj
and O
has B-acn
diabetes B-obj
, O
offer B-acn
antihypertensive B-mod
drug B-obj
treatment I-obj
. O

Gabapentin B-obj
should O
be O
considered B-mod
for O
the O
treatment B-obj
of O
patients B-acr
with O
neuropathic B-obj
pain I-obj
. O

Offer B-acn
a O
pancreatic B-mod
protocol I-mod
CT B-obj
scan I-obj
to O
people B-acr
with O
pancreatic B-mod
abnormalities B-obj
but O
no O
jaundice B-obj
. O

All O
patients B-acr
co-infected B-acn
with O
HIV B-obj
and O
HCV B-obj
genotype I-obj
1 I-obj
should O
be O
considered B-mod
for O
treatment B-obj
with O
a O
regimen B-obj
which O
includes B-acn
an O
HCV B-obj
protease I-obj
inhibitor I-obj
. O

If O
the O
person B-acr
is O
aged O
under B-mod
80 B-obj
years I-obj
with O
stage B-obj
1 I-obj
hypertension I-obj
and O
has B-acn
renal B-obj
disease I-obj
, O
offer B-acn
antihypertensive B-mod
drug B-obj
treatment I-obj
. O

If O
remission B-obj
is O
not O
achieved B-mod
within O
4 O
weeks O
, O
consider B-acn
adding O
a O
high-dose B-mod
oral I-mod
aminosalicylate B-obj
to O
the O
topical B-mod
aminosalicylate B-obj
or O
switching O
to O
a O
high-dose B-mod
oral I-mod
aminosalicylate B-obj
and O
a O
time-limited B-mod
course B-obj
of O
a O
topical B-mod
corticosteroid B-obj
. O

All O
patients B-acr
with O
chronic B-mod
HCV B-obj
infection I-obj
should O
be O
considered B-mod
for O
antiviral B-obj
therapy I-obj
. O

If O
the O
person B-acr
is O
aged O
under B-mod
80 B-obj
years I-obj
with O
reduced B-mod
ejection B-obj
fraction I-obj
, O
maintain B-acn
blood B-obj
pressure I-obj
below B-mod
150/90 I-mod
mmHg I-mod
. O

For O
early B-mod
stage I-mod
disease B-obj
, O
maintenance B-obj
cytotoxic I-obj
chemotherapy I-obj
should O
not O
be O
given B-mod
. O

Patients B-acr
with O
heart B-obj
failure I-obj
and O
clinical B-mod
signs B-obj
or O
symptoms B-obj
of O
fluid B-obj
overload I-obj
or O
congestion B-obj
should O
be O
considered B-mod
for O
diuretic B-mod
therapy B-obj
. O

For O
people B-acr
with O
an O
acute B-mod
cough B-obj
who O
are O
identified B-mod
at O
a O
face-to-face B-mod
clinical B-obj
examination I-obj
as O
at O
higher O
risk O
of O
complications O
, O
consider B-acn
an O
immediate B-mod
antibiotic B-obj
prescription I-obj
or O
a O
back-up B-mod
antibiotic B-obj
prescription I-obj
. O

Offer B-acn
urgent O
low-dose B-mod
non-contrast I-mod
CT B-obj
to O
adults B-acr
with O
suspected O
renal B-obj
colic I-obj
. O

For O
eligible B-mod
people B-obj
with O
stage B-obj
3A I-obj
NSCLC I-obj
who O
cannot O
tolerate B-acn
or O
who O
decline B-acn
chemoradiotherapy B-obj
, O
consider B-acn
radical B-mod
radiotherapy B-obj
. O

Do O
not O
routinely O
use B-acn
24-hour B-mod
urine B-obj
collection I-obj
to O
quantify B-acn
proteinuria B-obj
in O
pregnant B-mod
women B-obj
. O

Women B-acr
with O
stage B-obj
4 I-obj
ovarian I-obj
cancer I-obj
should O
be O
offered B-mod
bevacizumab B-obj
in O
combination O
with O
carboplatin B-obj
and O
paclitaxel B-obj
. O

If O
HbA1c B-acr
rises B-acn
to O
58 B-mod
mmol/mol I-mod
( I-mod
7.5 I-mod
% I-mod
) I-mod
, O
consider B-acn
insulin-based B-obj
treatment I-obj
and O
support B-acn
the O
person B-obj
to O
aim B-acn
for O
an O
HbA1c B-obj
level I-obj
of O
53 B-mod
mmol/mol I-mod
( I-mod
7 I-mod
% I-mod
) I-mod
. O

All O
women B-acr
with O
non-mucinous B-mod
ovarian B-obj
or O
fallopian B-obj
tube I-obj
cancer I-obj
should O
be O
offered B-mod
BRCA1 B-obj
and O
BRCA2 B-obj
mutation I-obj
testing I-obj
. O

Vaccination B-obj
in O
patients B-acr
with O
AIIRD B-obj
should O
ideally O
be O
administered B-mod
during O
stable B-mod
disease B-obj
. O

If O
the O
person B-acr
is O
with O
CKD B-obj
and O
vitamin B-obj
D I-obj
supplementation I-obj
is O
indicated B-mod
, O
offer B-acn
colecalciferol B-obj
or O
ergocalciferol B-obj
. O

Consider B-acn
surgical B-mod
mediastinal I-mod
staging B-obj
for O
people B-acr
with O
a O
negative B-mod
EBUS-TBNA B-obj
or O
EUS-FNA B-obj
if O
clinical B-mod
suspicion B-obj
of O
nodal B-obj
malignancy I-obj
is O
high O
and O
nodal B-obj
status I-obj
would O
affect B-acn
their O
treatment B-obj
plan I-obj
. O

Measure B-acn
serum B-obj
calcium I-obj
for O
people B-acr
who O
develop B-acn
a O
pancreatic B-obj
cancer I-obj
resection I-obj
. O

If O
cytological B-mod
or O
histological B-mod
samples B-acr
are O
needed B-mod
, O
offer B-acn
EUS B-obj
with O
EUS-guided B-mod
tissue B-obj
sampling I-obj
. O

In O
patients B-acr
with O
active B-mod
enthesitis B-obj
and/or O
dactylitis B-obj
and O
insufficient B-mod
response B-obj
to O
NSAIDs B-obj
or O
local B-mod
glucocorticoid B-obj
injections I-obj
, O
therapy B-obj
with O
a O
bDMARD B-obj
should O
be O
considered B-mod
, O
which O
according B-acn
to O
current B-mod
practice B-obj
is O
a O
TNF B-obj
inhibitor I-obj
. O

Patients B-acr
with O
suspected O
T3 B-obj
or O
T4 B-obj
disease I-obj
who O
are O
otherwise O
fit B-mod
for O
surgery B-obj
should O
not O
be O
denied B-mod
surgical B-obj
exploration I-obj
on O
the O
basis O
of O
a O
CT B-obj
scan I-obj
alone O
. O

In O
general O
, O
STIR B-obj
sequences I-obj
are O
sufficient B-mod
to O
detect B-acn
inflammation B-obj
and O
the O
use O
of O
contrast B-obj
medium I-obj
is O
not O
needed B-mod
. O

Offer B-acn
to O
carry O
out O
a O
blood B-obj
test I-obj
for O
rheumatoid B-obj
factor I-obj
in O
adults B-acr
with O
suspected B-mod
rheumatoid B-obj
arthritis I-obj
who O
are O
found B-mod
to O
have B-acn
synovitis B-obj
on O
clinical B-mod
examination B-obj
. O

Do O
not O
offer B-acn
bisphosphonates B-obj
for O
chronic B-mod
hypercalcaemia B-obj
of O
primary B-mod
hyperparathyroidism B-obj
. O

Consider B-acn
a O
bisphosphonate B-obj
to O
reduce B-acn
fracture B-obj
risk I-obj
for O
people B-acr
with O
primary B-mod
hyperparathyroidism B-obj
and O
increased B-mod
fracture B-obj
risk I-obj
. O

Offer B-acn
radical B-obj
resection I-obj
to O
people B-acr
with O
T1bN0 B-obj
oesophageal I-obj
adenocarcinoma I-obj
if O
they B-acr
are O
fit B-mod
enough O
to O
have B-acn
surgery B-obj
. O

Evaluate B-acn
PET-CT-positive B-obj
or O
enlarged B-mod
intrathoracic B-obj
nodes I-obj
using O
a O
systematic B-mod
approach B-obj
with O
EBUS-TBNA B-obj
and/or O
EUS-FNA B-obj
if O
nodal B-obj
status I-obj
would O
affect B-acn
the O
treatment B-obj
plan I-obj
. O

Do O
not O
measure B-acn
ionised B-mod
calcium B-obj
when O
testing O
for O
primary B-mod
hyperparathyroidism B-obj
. O

In O
patients B-acr
with O
permanent B-mod
AF B-obj
or O
persistent B-mod
AF B-obj
following O
a O
rate B-obj
control I-obj
strategy I-obj
and O
a O
resting B-mod
heart B-obj
rate I-obj
> O
110 O
bpm O
, O
appropriate B-mod
rate B-obj
control I-obj
therapy I-obj
should O
be O
instituted B-mod
with O
an O
initial B-mod
target B-obj
of O
resting B-mod
heart B-obj
rate I-obj
. O

Consider B-acn
a O
clinical B-mod
trial B-obj
as O
an O
alternative B-obj
to O
second-line B-mod
chemotherapy B-obj
for O
people B-acr
with O
oesophago-gastric B-obj
cancer I-obj
. O

Consider B-acn
alpha B-obj
blockers I-obj
for O
adults B-obj
, O
children B-obj
and O
young B-mod
people B-obj
with O
distal B-mod
ureteric B-obj
stones I-obj
less O
than O
10 B-mod
mm I-mod
. O

Consider B-acn
budesonide B-obj
for O
a O
first B-mod
presentation B-obj
or O
a O
single O
inflammatory B-mod
exacerbation B-obj
in O
a O
12-month O
period O
for O
people B-acr
who O
have B-acn
one O
or O
more O
of O
distal B-obj
ileal I-obj
, O
ileocaecal B-obj
or O
right-sided B-mod
colonic B-obj
disease I-obj
and O
if O
conventional B-obj
glucocorticosteroids I-obj
are O
contraindicated B-mod
, O
or O
if O
the O
person B-acr
declines B-acn
or O
cannot O
tolerate B-acn
them B-obj
. O

If O
clinical B-mod
evaluation B-obj
or O
lung B-obj
function I-obj
testing I-obj
indicates B-acn
an O
inadequate B-mod
response B-obj
to O
rhDNase B-obj
, O
consider B-acn
both O
rhDNase B-obj
and O
hypertonic B-mod
sodium B-obj
chloride I-obj
or O
hypertonic B-mod
sodium B-obj
chloride I-obj
alone O
. O

If O
remission B-obj
is O
not O
achieved B-mod
within O
4 O
weeks O
, O
stop B-acn
the O
topical B-mod
aminosalicylate B-obj
and O
offer B-acn
a O
high-dose B-mod
oral I-mod
aminosalicylate B-obj
with O
a O
time-limited B-mod
course B-obj
of O
an O
oral B-mod
corticosteroid B-obj
. O

Adjuvant B-mod
chemotherapy B-obj
should O
be O
considered B-mod
for O
all O
patients B-acr
with O
breast B-obj
cancer I-obj
where O
benefit B-acr
outweighs B-acn
risk B-obj
. O

For O
children B-acr
who O
are O
allergic B-mod
to O
penicillins B-obj
, O
consider B-acn
an O
alternative O
oral B-mod
anti-Staphylococcus B-obj
aureus I-obj
agent I-obj
. O

Patients B-acr
with O
hepatitis B-obj
C I-obj
virus I-obj
and O
concurrent B-mod
operable I-mod
hepatocellular B-obj
carcinoma I-obj
should O
be O
offered B-mod
liver B-obj
transplantation I-obj
. O

Do O
not O
offer B-acn
antispasmodics B-obj
to O
adults B-obj
, O
children B-obj
and O
young B-mod
people B-obj
with O
suspected B-mod
renal B-obj
colic I-obj
. O

Aim B-acn
for O
a O
target B-mod
clinic I-mod
blood B-obj
pressure I-obj
below B-mod
150/90 I-mod
mmHg I-mod
in O
people B-obj
aged O
80 B-obj
years I-obj
and O
over B-mod
with O
treated B-mod
hypertension B-obj
. O

Do O
not O
offer B-acn
antihypertensive B-mod
drug B-obj
treatment I-obj
if O
the O
person B-acr
is O
with O
type B-obj
1 I-obj
diabetes I-obj
. O

For O
people B-acr
who O
cannot O
tolerate B-acn
aminosalicylates B-obj
, O
consider B-acn
a O
time-limited B-mod
course B-obj
of O
an O
oral B-mod
corticosteroid B-obj
. O

Offer B-acn
monotherapy B-obj
with O
a O
conventional B-mod
glucocorticosteroid B-obj
to O
induce B-acn
remission B-obj
in O
people B-acr
with O
a O
first B-mod
presentation B-obj
or O
a O
single O
inflammatory B-mod
exacerbation B-obj
of O
Crohn's B-obj
disease I-obj
in O
a O
12-month O
period O
. O

Offer B-acn
intravenous B-mod
paracetamol B-obj
to O
adults B-obj
, O
children B-obj
and O
young B-mod
people B-obj
with O
suspected B-mod
renal B-obj
colic I-obj
if O
NSAIDs B-acr
are O
contraindicated B-mod
or O
are O
not O
giving B-acn
sufficient B-mod
pain B-obj
relief I-obj
. O

If O
the O
patient B-acr
is O
already O
on O
an O
ACE B-obj
inhibitor I-obj
, O
the O
ACE B-obj
inhibitor I-obj
should O
be O
stopped B-mod
for O
36 O
hours O
before O
initiating B-acn
sacubitril B-obj
/ O
valsartan B-obj
to O
minimise B-acn
the O
risk B-obj
of O
angioedema B-obj
. O

Offer B-acn
standard B-mod
structural I-mod
MRI B-obj
as O
the O
initial B-mod
diagnostic B-obj
test I-obj
for O
suspected B-mod
glioma B-obj
, O
unless O
MRI B-obj
is O
contraindicated B-mod
. O

Screening B-obj
for O
asymptomatic B-obj
atherosclerotic I-obj
plaques I-obj
by O
use O
of O
carotid B-obj
ultrasound I-obj
may O
be O
considered B-mod
as O
part O
of O
the O
CVD B-obj
risk I-obj
evaluation I-obj
in O
patients B-acr
with O
RA B-obj
. O

For O
patients B-acr
receiving B-acn
a O
protease B-obj
inhibitor I-obj
in O
combination O
with O
pegylated B-obj
IFN I-obj
and O
ribavirin B-obj
therapy I-obj
, O
consider B-acn
ribavirin B-obj
dose I-obj
reduction I-obj
as O
an O
alternative B-obj
to O
the O
addition O
of O
EPO B-obj
for O
controlling B-acn
anaemia B-obj
. O

Avoid B-acn
verapamil B-obj
, O
diltiazem B-obj
and O
short-acting B-mod
dihydropyridine B-obj
agents I-obj
in O
people B-acr
who O
have B-acn
heart B-obj
failure I-obj
with O
reduced B-mod
ejection B-obj
fraction I-obj
. O

Do O
not O
offer B-acn
budesonide B-obj
or O
aminosalicylate B-obj
treatment I-obj
for O
severe B-mod
presentations B-obj
or O
exacerbations B-obj
. O

Consider B-acn
measuring O
albumin-adjusted B-obj
serum I-obj
calcium I-obj
for O
people B-acr
with O
chronic B-mod
non-differentiated I-mod
symptoms B-obj
. O

Human B-obj
papillomavirus I-obj
vaccination I-obj
should O
be O
considered B-mod
in O
selected B-mod
patients B-acr
with O
AIIRD B-mod
. O

Offer B-acn
systemic B-mod
combination B-obj
chemotherapy I-obj
to O
people B-acr
with O
locally O
advanced B-mod
pancreatic B-obj
cancer I-obj
who O
are O
well B-mod
enough O
to O
tolerate B-acn
it B-obj
. O

Vaccination B-obj
in O
patients B-acr
with O
AIIRD B-obj
can O
be O
administered B-mod
during O
the O
use O
of O
disease-modifying B-mod
antirheumatic B-obj
drugs I-obj
and O
tumour B-mod
necrosis I-mod
factor I-mod
alpha B-obj
blocking I-obj
agents I-obj
but O
should O
ideally O
be O
administered B-mod
before O
starting B-acn
B B-obj
cell I-obj
depleting I-obj
biological I-obj
therapy I-obj
. O

Provide B-acn
an O
accessible B-mod
resource B-obj
to O
promote B-acn
best B-mod
practice B-obj
in O
the O
management B-obj
of O
patients B-obj
using B-acn
medium/high-dose B-mod
GCs B-obj
to O
general B-mod
practitioners B-obj
. O

In O
patients B-acr
who O
fail B-acn
to O
respond B-acn
adequately B-mod
to O
a O
bDMARD B-obj
, O
switching B-acn
to O
another O
bDMARD B-obj
should O
be O
considered B-mod
, O
including O
switching B-acn
between O
TNF B-obj
inhibitors I-obj
. O

Patients B-acr
undergoing B-acn
surgical B-mod
revascularisation B-obj
of O
the O
left B-mod
anterior I-mod
descending B-obj
coronary I-obj
artery I-obj
should O
receive B-acn
an O
internal B-mod
mammary B-obj
artery I-obj
graft I-obj
. O

All O
patients B-acr
with O
invasive B-mod
breast B-obj
cancer I-obj
who O
are O
operable B-mod
should O
have B-acn
axillary B-obj
surgery I-obj
. O

Offer B-acn
a O
non-steroidal B-mod
anti-inflammatory I-mod
drug B-obj
by O
any O
route O
as O
first-line B-mod
treatment B-obj
for O
adults B-acr
, O
children B-acr
and O
young B-mod
people B-acr
with O
suspected B-mod
renal B-obj
colic I-obj
. O

The O
routine B-mod
use B-obj
of O
aspirin B-obj
to O
reduce B-acn
perioperative B-mod
cardiac B-obj
events I-obj
in O
patients B-acr
undergoing B-acn
non O
cardiac B-obj
surgery I-obj
, O
including O
those O
with O
known O
stable B-mod
CAD B-obj
, O
is O
not O
recommended B-mod
. O

Carboplatin B-obj
AUC I-obj
6 O
and O
paclitaxel B-obj
80 I-obj
mg/m2 I-obj
may O
be O
considered B-mod
for O
the O
treatment O
of O
first B-mod
line I-mod
ovarian B-obj
cancer I-obj
. O

Monitor B-acn
the O
response B-obj
to O
titration O
of O
medicines O
closely O
in O
people B-acr
who O
have B-acn
heart B-obj
failure I-obj
with O
reduced B-mod
ejection B-obj
fraction I-obj
and O
chronic B-obj
kidney I-obj
disease I-obj
. O

Amitriptyline B-obj
should O
be O
considered B-mod
for O
the O
treatment B-obj
of O
patients B-acr
with O
fibromyalgia B-obj
and O
neuropathic B-obj
pain I-obj
. O

Do O
not O
offer B-acn
azathioprine B-obj
or O
mercaptopurine B-obj
if O
TPMT B-obj
activity I-obj
is O
deficient B-mod
. O

If O
the O
person B-acr
is O
with O
CKD B-obj
and O
beta-blocker B-obj
, O
consider B-acn
starting O
antihypertensive B-obj
drug I-obj
. O

Offer B-acn
bisphosphonates B-obj
if O
indicated O
for O
the O
prevention B-obj
and O
treatment B-obj
of O
osteoporosis B-obj
in O
people B-acr
with O
a O
GFR B-obj
of O
30 B-mod
ml/min/1.73m2 I-mod
or O
more B-mod
. O

Pregabalin B-obj
is O
recommended B-mod
for O
the O
treatment B-obj
of O
patients B-acr
with O
neuropathic B-obj
pain I-obj
if O
other O
first B-mod
and O
second B-mod
line I-mod
pharmacological B-obj
treatments I-obj
have O
failed B-acn
. O

Do O
not O
offer B-acn
pre-treatment B-mod
stenting B-obj
to O
adults B-acr
having B-acn
shockwave B-mod
lithotripsy B-obj
for O
ureteric B-obj
or O
renal B-obj
stones I-obj
. O

A O
combination O
of O
digoxin B-obj
with O
either O
a O
beta-blocker B-obj
or O
diltiazem B-obj
should O
be O
considered B-mod
to O
control B-acn
heart B-obj
rate I-obj
in O
patients B-acr
with O
atrial B-obj
fibrillation I-obj
. O

For O
adults B-acr
with O
sudden O
onset O
acute B-mod
vestibular B-obj
syndrome I-obj
, O
a O
HINTS B-obj
test I-obj
should O
be O
performed B-acn
if O
a O
healthcare B-obj
professional I-obj
with O
training O
and O
experience O
in O
the O
use O
of O
this O
test O
is O
available B-mod
. O

For O
people B-acr
with O
an O
acute B-mod
cough B-obj
who O
are O
identified B-mod
at O
a O
face-to-face B-mod
clinical B-obj
examination I-obj
as O
systemically O
very O
unwell B-mod
, O
offer B-acn
an O
immediate B-mod
antibiotic B-obj
prescription I-obj
. O

Routine B-mod
surgery B-obj
for O
limited B-mod
disease B-obj
SCLC O
is O
not O
recommended B-mod
. O

Patients B-acr
having B-acn
radical B-obj
radiotherapy I-obj
should O
be O
given B-mod
CHART B-obj
in O
preference O
to O
60 B-obj
Gy I-obj
in O
30 O
fractions O
over O
six O
weeks O
. O

Offer B-acn
people B-acr
diagnosed O
with O
cerebral B-mod
venous I-mod
sinus B-obj
thrombosis I-obj
full-dose B-mod
anticoagulation B-obj
treatment I-obj
unless O
there O
are O
comorbidities O
that O
preclude O
its O
use O
. O

If O
long-term B-mod
medium/high-dose I-mod
GC B-obj
therapy I-obj
is O
anticipated B-mod
to O
be O
necessary B-mod
, O
actively B-mod
consider B-acn
GC-sparing B-mod
therapy B-obj
. O

In O
patients B-acr
with O
ankylosing B-mod
spondylitis B-obj
, O
initial B-mod
conventional I-mod
radiography B-obj
of O
the O
lumbar B-obj
and O
cervical B-obj
spine I-obj
is O
recommended B-mod
to O
detect B-acn
syndesmophytes B-obj
, O
which O
are O
predictive B-mod
of O
development B-obj
of O
new B-mod
syndesmophytes B-obj
. O

Combination B-obj
therapies I-obj
should O
be O
considered B-mod
for O
patients B-acr
with O
neuropathic B-obj
pain I-obj
. O

If O
there O
is O
no O
improvement B-obj
by O
at O
most O
3 O
months O
after O
the O
start B-obj
of O
treatment B-obj
or O
the O
target B-obj
has O
not O
been O
reached B-mod
by O
6 O
months O
, O
therapy B-obj
should O
be O
adjusted B-mod
. O

Give B-acn
a O
loading B-mod
dose B-obj
of O
20 O
mg/kg O
of O
caffeine B-obj
citrate I-obj
, O
followed B-acn
24 O
hours O
later O
by O
a O
maintenance B-obj
dosage I-obj
of O
5 O
mg/kg O
once O
daily O
, O
increasing B-acn
up O
to O
20 O
mg/kg O
daily O
if O
episodes B-acr
of O
apnoea O
persist B-acn
. O

In O
patients B-acr
undergoing B-acn
multiple B-mod
coronary B-obj
artery I-obj
bypass I-obj
grafting I-obj
, O
use O
of O
both O
internal B-mod
mammary B-obj
arteries I-obj
should O
be O
considered B-mod
. O

If O
further B-mod
treatment B-obj
is O
needed B-mod
, O
consider B-acn
adding O
a O
time-limited B-mod
course B-obj
of O
a O
topical B-mod
or O
an O
oral B-mod
corticosteroid B-obj
. O

Offer B-acn
parathyroid B-obj
surgery I-obj
to O
women B-acr
who O
have B-acn
primary B-mod
hyperparathyroidism B-obj
and O
are O
considering B-acn
pregnancy B-obj
. O

Assess B-acn
the O
ER B-obj
status I-obj
of O
all O
invasive B-mod
breast B-obj
cancers I-obj
using B-acn
standardised B-mod
and O
quality-assured B-mod
immunohistochemical B-obj
techniques I-obj
, O
and O
report B-acn
the O
results B-obj
quantitatively B-mod
. O

Consider B-acn
measuring O
anti-CCP B-mod
antibodies B-obj
in O
adults B-acr
with O
suspected B-mod
RA B-obj
if O
they B-acr
are O
negative B-mod
for O
rheumatoid B-mod
factor B-obj
. O

Patients B-acr
with O
, O
or O
at O
risk B-obj
of O
, O
GC-induced B-mod
osteoporosis B-obj
should O
receive B-acn
appropriate B-mod
preventive/therapeutic I-mod
interventions B-obj
. O

If O
HbA1c B-acr
rises B-acn
to O
58 B-mod
mmol/mol I-mod
( I-mod
7.5 I-mod
% I-mod
) I-mod
, O
consider B-acn
dual B-mod
therapy B-obj
with O
metformin B-obj
and O
a O
DPP-4i B-obj
, O
metformin B-obj
and O
pioglitazone B-obj
, O
metformin B-obj
and O
an O
SU B-obj
, O
metformin B-obj
and O
an O
SGLT-2i B-obj
, O
and O
support B-acn
the O
person B-obj
to O
aim B-acn
for O
an O
HbA1c B-obj
level I-obj
of O
53 B-mod
mmol/mol I-mod
( I-mod
7 I-mod
% I-mod
) I-mod
. O

Offer B-acn
endocrine B-obj
therapy I-obj
after O
breast-conserving B-obj
surgery I-obj
for O
women B-acr
with O
ER-positive B-mod
DCIS B-obj
if O
radiotherapy B-obj
is O
recommended B-mod
but O
not O
received B-mod
. O

Offer B-acn
an O
alternative B-mod
antiplatelet B-obj
agent I-obj
to O
anyone B-obj
with O
acute B-mod
ischaemic B-obj
stroke I-obj
who O
is O
allergic B-mod
to O
or O
genuinely O
intolerant B-mod
of O
aspirin B-obj
. O

Intravenous B-obj
amiodarone I-obj
should O
be O
considered B-mod
in O
the O
management O
of O
patients B-acr
with O
haemodynamically B-mod
stable I-mod
sustained B-obj
monomorphic I-obj
VT I-obj
. O

Calcium B-obj
channel I-obj
blocker I-obj
therapy I-obj
is O
not O
recommended B-mod
for O
reduction B-obj
in O
sudden B-mod
death B-obj
or O
all O
cause O
mortality O
in O
patients B-acr
following B-acn
ACS B-obj
. O

Offer B-acn
metformin B-obj
as O
the O
initial B-mod
drug B-obj
treatment I-obj
for O
adults B-obj
with O
type B-obj
2 I-obj
diabetes I-obj
. O

Blood B-obj
pressure I-obj
reduction I-obj
to O
185/110 B-mod
mmHg I-mod
or O
lower O
should O
be O
considered O
in O
people B-acr
who O
are O
candidates B-mod
for O
intravenous B-obj
thrombolysis I-obj
. O

Aromatase B-obj
inhibitor I-obj
is O
recommended B-mod
for O
ER B-mod
positive I-mod
postmenopausal B-obj
women I-obj
receiving B-acn
neoadjuvant B-mod
endocrine B-obj
therapy I-obj
. O

A O
resting B-mod
ECG B-obj
should O
be O
performed B-mod
in O
patients B-acr
with O
suspected B-mod
cardiac B-obj
chest I-obj
pain I-obj
. O

Patients B-acr
with O
chronic B-mod
hepatitis B-obj
B I-obj
and O
C B-obj
co-infection I-obj
should O
be O
considered B-mod
for O
treatment B-obj
with O
pegylated B-obj
IFN I-obj
and O
weight B-mod
based I-mod
ribavirin B-obj
. O

In O
hyposplenic/asplenic B-mod
patients B-acr
with O
AIIRD B-obj
influenza I-obj
, O
pneumococcal B-obj
, O
Haemophilus B-obj
influenzae I-obj
b I-obj
and O
meningococcal B-obj
C I-obj
, O
vaccinations B-obj
are O
recommended B-mod
. O

Consider B-acn
adding O
azathioprine B-obj
or O
mercaptopurine B-obj
to O
a O
conventional B-mod
glucocorticosteroid B-obj
or O
budesonide B-obj
to O
induce B-acn
remission B-obj
of O
Crohn's B-obj
disease I-obj
if O
there O
are O
2 O
or O
more O
inflammatory B-mod
exacerbations B-obj
in O
a O
12 O
month O
period O
or O
the O
glucocorticosteroid B-obj
dose I-obj
cannot O
be O
tapered B-mod
. O

Offer B-acn
radiotherapy B-obj
using B-acn
60 B-obj
Gy I-obj
in O
30 O
fractions O
with O
concomitant B-obj
temozolomide I-obj
for O
people B-acr
aged O
around B-mod
70 B-obj
or O
under B-mod
. O

Patients B-acr
with O
advanced B-mod
liver B-obj
disease I-obj
should O
be O
given B-mod
nutritional B-obj
support I-obj
to O
minimise B-acn
malnutrition B-obj
. O

Offer B-acn
an O
MRA B-obj
, O
in O
addition O
to O
an O
ACE B-obj
inhibitor I-obj
( O
or O
ARB B-obj
) O
and O
beta-blocker B-obj
, O
to O
people B-acr
who O
have B-acn
heart B-obj
failure I-obj
with O
reduced B-mod
ejection B-obj
fraction I-obj
if O
they O
continue B-acr
to O
have B-acn
symptoms B-obj
of O
heart B-obj
failure I-obj
. O

Consider B-acn
enteric-coated B-obj
pancreatin I-obj
before B-mod
and O
after B-mod
pancreatic B-obj
cancer I-obj
resection I-obj
. O

CVD B-obj
risk I-obj
management I-obj
should O
be O
carried B-mod
out O
according O
to O
national B-obj
guidelines I-obj
in O
RA B-obj
, O
AS B-obj
or O
PsA B-obj
. O

Interpret B-acn
proteinuria B-obj
measurements I-obj
for O
pregnant B-mod
women B-obj
in O
the O
context O
of O
a O
full O
clinical O
review O
of O
symptoms O
, O
signs O
and O
other O
investigations O
for O
pre-eclampsia O
. O

All O
patients B-acr
with O
stable B-mod
angina B-obj
due O
to O
atherosclerotic B-obj
disease I-obj
should O
receive B-acn
long B-mod
term I-mod
standard B-obj
aspirin I-obj
and O
statin B-obj
therapy I-obj
. O

Erythropoietin B-obj
is O
not O
recommended B-mod
for O
patients B-acr
with O
heart B-obj
failure I-obj
with O
reduced B-mod
ejection B-obj
fraction I-obj
and O
iron B-obj
deficiency I-obj
. O

Monitor B-acn
for O
neutropenia B-obj
in O
people B-acr
taking B-acn
azathioprine B-obj
or O
mercaptopurine B-obj
even O
if O
they B-acr
have B-acn
normal B-mod
TPMT B-obj
activity I-obj
. O

Consider B-acn
opioids B-obj
for O
adults B-acr
, O
children B-acr
and O
young B-mod
people B-acr
with O
suspected B-mod
renal B-obj
colic I-obj
if O
both O
NSAIDs B-obj
and O
intravenous B-mod
paracetamol B-obj
are O
contraindicated B-mod
or O
are O
not O
giving B-acn
sufficient B-mod
pain B-obj
relief I-obj
. O

All O
women B-acr
with O
high B-mod
grade I-mod
early I-mod
stage I-mod
ovarian B-obj
cancer I-obj
should O
be O
considered B-mod
for O
adjuvant B-mod
chemotherapy B-obj
. O

Offer B-acn
antihypertensive B-mod
drug B-obj
treatment I-obj
for O
heart B-obj
failure I-obj
with O
treated B-mod
hypertension B-obj
. O

bDMARDs B-obj
and O
tsDMARDs B-obj
should O
be O
combined B-mod
with O
a O
csDMARD B-obj
. O

Do O
not O
offer B-acn
an O
antibiotic B-obj
to O
treat B-acn
an O
acute B-mod
cough B-obj
associated O
with O
an O
upper B-mod
respiratory I-mod
tract B-obj
infection I-obj
in O
people B-acr
who O
are O
not O
systemically O
very O
unwell B-mod
or O
at O
higher B-mod
risk B-obj
of O
complications B-obj
. O

Women B-acr
with O
platinum B-mod
resistant I-mod
ovarian B-obj
cancer I-obj
should O
be O
considered B-mod
for O
treatment B-obj
with O
paclitaxel B-obj
or O
single B-mod
agent I-mod
pegylated B-obj
liposomal I-obj
doxorubicin I-obj
hydrochloride I-obj
. O

For O
people B-acr
who O
have B-acn
had O
pancreatoduodenectomy B-obj
and O
who O
have B-acn
a O
functioning B-mod
gut B-obj
, O
offer B-acn
early O
enteral B-mod
nutrition B-obj
rather O
than O
parenteral B-obj
nutrition B-obj
. O

Give B-acn
oral B-mod
antibiotics B-obj
first O
line O
if O
the O
person B-acr
can O
take B-acn
oral B-mod
medicines B-obj
, O
and O
the O
severity B-mod
of O
their O
condition B-acr
does O
not O
require B-acn
intravenous B-mod
antibiotics B-obj
. O

Consider B-acn
stone B-obj
analysis I-obj
for O
adults B-obj
with O
ureteric B-obj
or O
renal B-obj
stones I-obj
. O

For O
preterm B-mod
babies B-acr
who O
need B-acn
invasive B-mod
ventilation B-obj
but O
VTV B-obj
and O
HFOV B-obj
are O
not O
available B-mod
or O
not O
suitable B-mod
, O
consider B-acn
synchronised B-mod
intermittent I-mod
mandatory I-mod
ventilation B-obj
. O

Consider B-acn
oral B-mod
sodium B-obj
bicarbonate I-obj
supplementation I-obj
for O
people B-obj
with O
both B-mod
a O
GFR B-obj
less B-mod
than I-mod
30 B-mod
ml/min/1.73m2 I-mod
and O
a O
serum B-obj
bicarbonate I-obj
concentration I-obj
of O
less B-mod
than I-mod
20 B-mod
mmol/litre I-mod
. O

Do O
not O
offer B-acn
aspirin B-obj
for O
the O
primary B-mod
prevention I-mod
of O
cardiovascular B-obj
disease I-obj
to O
adults B-obj
with O
type B-obj
1 I-obj
diabetes I-obj
. O

Consider B-acn
an O
ARB B-obj
licensed O
for O
heart B-obj
failure I-obj
as O
an O
alternative B-obj
to O
an O
ACE B-obj
inhibitor I-obj
for O
people B-acr
who O
have B-acn
heart B-obj
failure I-obj
with O
reduced B-mod
ejection B-obj
fraction I-obj
and O
intolerable B-mod
side B-obj
effects I-obj
with O
ACE B-obj
inhibitors I-obj
. O

For O
women B-acr
with O
a O
cerebrovascular B-obj
malformation I-obj
at O
low B-mod
risk B-obj
of O
intracranial B-obj
bleeding I-obj
, O
manage B-acn
the O
second B-obj
stage I-obj
of O
labour B-obj
based O
on O
the O
woman's B-mod
preference B-obj
and O
obstetric B-obj
indications I-obj
. O

To O
induce B-acn
remission B-obj
in O
people B-acr
with O
a O
mild-to-moderate B-mod
first I-mod
presentation B-obj
or O
inflammatory B-mod
exacerbation B-obj
of O
extensive B-mod
ulcerative B-obj
colitis I-obj
, O
offer B-acn
a O
topical B-mod
aminosalicylate B-obj
and O
a O
high-dose B-mod
oral I-mod
aminosalicylate B-obj
as O
first-line B-mod
treatment B-obj
. O

Patients B-acr
with O
compensated B-mod
cirrhosis B-obj
should O
be O
considered B-mod
for O
therapy B-obj
, O
unless O
contraindicated B-mod
. O

Tricyclic B-obj
antidepressants I-obj
should O
not O
be O
used B-mod
for O
the O
management B-obj
of O
pain B-obj
in O
patients B-acr
with O
chronic B-mod
low B-obj
back I-obj
pain I-obj
. O

Do O
not O
routinely B-mod
repeat B-acn
PTH B-obj
measurement I-obj
in O
primary O
care O
. O

When O
adequate B-mod
control B-obj
of O
anginal B-mod
symptoms B-obj
is O
not O
achieved B-mod
with O
beta B-obj
blockade I-obj
, O
addition O
of O
a O
calcium B-obj
channel I-obj
blocker I-obj
should O
be O
considered B-mod
. O

Verapamil B-obj
and O
diltiazem B-obj
may O
be O
used B-mod
for O
prophylaxis B-obj
of O
atrial B-obj
fibrillation I-obj
following B-acn
CABG B-obj
surgery I-obj
. O

Consider B-acn
adding O
methotrexate B-obj
to O
a O
conventional B-mod
glucocorticosteroid B-obj
or O
budesonide B-obj
to O
induce B-acn
remission B-obj
in O
people B-acr
who O
cannot O
tolerate B-acn
azathioprine B-obj
or O
mercaptopurine B-obj
. O

Offer B-acn
a O
mucoactive B-obj
agent I-obj
to O
people B-acr
with O
cystic B-obj
fibrosis I-obj
who O
have B-acn
clinical B-mod
evidence B-obj
of O
lung B-obj
disease I-obj
. O

If O
a O
patient B-acr
is O
in O
persistent B-mod
remission B-obj
, O
tapering B-acn
the O
csDMARD B-obj
could O
be O
considered B-mod
. O

Offer B-acn
image-guided B-mod
biopsy B-obj
to O
people B-acr
with O
peripheral B-mod
lung B-obj
lesions I-obj
when O
treatment B-acr
can O
be O
planned B-acn
on O
the O
basis O
of O
this O
test O
. O

Patients B-acr
with O
acute B-mod
coronary B-obj
syndrome I-obj
should O
have B-acn
continuous B-mod
cardiac B-obj
rhythm I-obj
monitoring I-obj
. O

Olaparib B-obj
monotherapy I-obj
should O
be O
considered B-mod
for O
maintenance O
treatment B-obj
after O
response B-obj
to O
platinum B-obj
for O
patients B-acr
with O
relapsed B-mod
platinum I-mod
sensitive I-mod
BRCA B-obj
mutated I-obj
ovarian I-obj
cancer I-obj
. O

Adjuvant B-mod
trastuzumab B-obj
should O
be O
considered B-mod
in O
all O
patients B-acr
with O
HER B-obj
2 I-obj
positive I-obj
breast I-obj
cancer I-obj
who O
receive B-acn
adjuvant B-mod
chemotherapy B-obj
. O

Do O
not O
routinely O
offer B-acn
an O
antibiotic B-obj
to O
treat B-acn
an O
acute B-mod
cough B-obj
associated O
with O
acute B-mod
bronchitis B-obj
in O
people B-acr
who O
are O
not O
systemically O
very O
unwell B-mod
or O
at O
higher O
risk O
of O
complications O
. O

Maintain B-acn
blood B-obj
pressure I-obj
below B-mod
140/90 I-mod
mmHg I-mod
for O
people B-acr
who O
have B-acn
symptoms B-obj
of O
stage B-obj
1 I-obj
hypertension I-obj
. O

Patients B-acr
with O
genotype B-obj
1 I-obj
infection I-obj
who O
fail B-acn
to O
achieve B-acn
an O
EVR B-obj
at O
12 O
weeks O
should O
be O
considered B-mod
for O
cessation B-obj
of O
treatment B-obj
. O

Offer B-acn
bisphosphonates B-obj
as O
adjuvant B-mod
therapy B-obj
to O
postmenopausal B-mod
women B-obj
with O
node-positive B-mod
invasive I-mod
breast B-obj
cancer I-obj
. O

Patients B-acr
with O
NSCLC B-obj
stage I-obj
1 I-obj
and O
2 B-obj
who O
are O
medically B-mod
inoperable I-mod
or O
who O
do O
not O
consent B-acn
to O
surgery B-obj
should O
be O
offered B-mod
radical B-obj
radiotherapy I-obj
. O

Furthermore O
, O
US B-obj
or O
MRI B-obj
might O
be O
used B-mod
to O
detect B-acn
peripheral B-mod
arthritis B-obj
, O
tenosynovitis B-obj
and O
bursitis B-obj
. O

If O
HbA1c B-acr
rises B-acn
to O
48 B-mod
mmol/mol I-mod
( I-mod
6.5 I-mod
% I-mod
) I-mod
on O
lifestyle O
interventions O
, O
consider B-acn
a O
DPP-4i B-obj
, O
pioglitazone B-obj
, O
an O
SU B-obj
, O
an O
SGLT-2i B-obj
, O
and O
support B-acn
the O
person B-obj
to O
aim B-acn
for O
an O
HbA1c B-obj
level I-obj
of O
48 B-mod
mmol/mol I-mod
( I-mod
6.5 I-mod
% I-mod
) I-mod
for O
people B-obj
on O
a O
DPP-4i B-obj
, O
SGLT-2i B-obj
or O
pioglitazone B-obj
or O
53 B-mod
mmol/mol I-mod
( I-mod
7 I-mod
% I-mod
) I-mod
for O
people B-obj
on O
an O
SU B-obj
. O

Patients B-acr
with O
early B-mod
stage I-mod
peripheral B-obj
lung I-obj
cancers I-obj
who O
are O
not O
suitable B-mod
for O
surgery B-obj
should O
be O
considered B-mod
for O
stereotactic B-mod
ablative I-mod
radiotherapy B-obj
. O

In O
patients B-acr
with O
predominantly B-mod
axial B-obj
disease I-obj
that O
is O
active B-mod
and O
has B-acn
insufficient B-mod
response B-obj
to O
NSAIDs B-obj
, O
therapy B-obj
with O
a O
bDMARD B-obj
should O
be O
considered B-mod
, O
which O
according B-acn
to O
current B-mod
practice B-obj
is O
a O
TNF B-obj
inhibitor I-obj
. O

Offer B-acn
contrast-enhanced B-mod
brain B-obj
CT I-obj
if O
the O
person B-acr
has O
established B-acn
cardiovascular B-obj
disease I-obj
. O

Sublingual B-mod
glyceryl B-obj
trinitrate I-obj
tablets I-obj
or O
spray B-obj
should O
be O
used B-mod
for O
the O
immediate B-mod
relief B-obj
of O
angina B-obj
and O
before O
performing B-acn
activities B-obj
that O
are O
known O
to O
bring B-acn
on O
angina B-obj
. O

Herpes B-obj
zoster I-obj
vaccination I-obj
may O
be O
considered B-mod
in O
patients B-acr
with O
AIIRD B-obj
. O

Class B-obj
1 I-obj
antiarrhythmic I-obj
drugs I-obj
should O
not O
be O
used B-mod
for O
treatment B-obj
of O
premature B-mod
ventricular B-obj
beats I-obj
or O
non O
sustained B-mod
VT B-obj
in O
patients B-acr
with O
previous O
MI B-obj
. O

Do O
not O
routinely O
use B-acn
MRI B-obj
to O
assess B-acn
the O
stage O
of O
the O
primary B-mod
tumour B-obj
(T-stage) I-obj
in O
non-small-cell B-mod
lung B-obj
cancer I-obj
. O

For O
people B-acr
with O
cystic B-obj
fibrosis I-obj
who O
develop B-acn
a O
Haemophilus B-obj
influenzae I-obj
infection I-obj
but O
do O
not O
have B-acn
clinical B-mod
evidence B-obj
of O
pulmonary B-obj
infection I-obj
, O
treat B-acn
with O
an O
appropriate O
oral B-mod
antibiotic B-obj
. O

Amiodarone B-obj
therapy I-obj
is O
not O
recommended B-mod
for O
patients B-acr
following B-acn
ACS B-obj
or O
patients B-acr
with O
congestive B-mod
heart B-obj
failure I-obj
who O
do O
not O
have B-acn
sustained B-mod
ventricular B-obj
arrhythmias I-obj
or O
atrial B-obj
fibrillation I-obj
. O

Offer B-acn
platinum-based B-mod
combination B-obj
chemotherapy I-obj
to O
people B-acr
with O
extensive-stage B-mod
disease B-obj
SCLC I-obj
if O
they B-acr
are O
fit B-mod
enough I-mod
. O

Maintain B-acn
blood B-obj
pressure I-obj
below B-mod
130/80 I-mod
mmHg I-mod
or O
lower B-mod
for O
people B-acr
who O
have B-acn
heart B-obj
failure I-obj
with O
stage B-obj
2 I-obj
diabetes I-obj
. O

If O
ACE B-obj
inhibitors O
are O
not O
tolerated B-mod
, O
substitute B-acn
angiotensin B-obj
2 I-obj
receptor I-obj
antagonists I-obj
. O

Duloxetine B-obj
should O
be O
considered B-mod
for O
the O
treatment B-obj
of O
patients B-acr
with O
diabetic B-mod
neuropathic B-obj
pain I-obj
if O
other O
first B-mod
or O
second B-mod
line I-mod
pharmacological B-obj
therapies I-obj
have O
failed B-acn
. O

Assess B-acn
the O
PR B-obj
status I-obj
of O
all O
invasive B-mod
breast B-obj
cancers I-obj
using B-acn
standardised B-mod
and O
quality-assured B-mod
immunohistochemical B-obj
techniques I-obj
, O
and O
report B-acn
the O
results B-obj
quantitatively B-mod
. O

In O
patients B-acr
with O
peripheral B-mod
arthritis B-obj
and O
an O
inadequate B-mod
response B-obj
to O
at O
least O
one O
csDMARD B-obj
, O
in O
whom O
bDMARDs B-obj
are O
not O
appropriate B-mod
, O
a O
targeted B-mod
synthetic B-obj
DMARD I-obj
such O
as O
a O
PDE4-inhibitor B-obj
may O
be O
considered B-mod
. O

Offer B-acn
an O
ACE B-obj
inhibitor I-obj
and O
a O
beta-blocker B-obj
licensed O
for O
heart B-obj
failure I-obj
to O
people B-acr
who O
have B-acn
heart B-obj
failure I-obj
with O
reduced B-mod
ejection B-obj
fraction I-obj
. O

All O
patients B-acr
co-infected B-acn
with O
HCV B-obj
and O
HIV B-obj
should O
be O
considered B-mod
for O
HCV B-obj
treatment I-obj
. O

All O
patients B-acr
with O
stable B-mod
angina B-obj
should O
be O
considered B-mod
for O
treatment B-obj
with O
angiotensin B-obj
converting I-obj
enzyme I-obj
inhibitors I-obj
. O

Patients B-acr
with O
lung B-obj
cancer I-obj
who O
have B-acn
symptomatic B-mod
bone B-obj
metastases I-obj
should O
be O
considered B-mod
for O
treatment B-obj
with O
a O
bisphosphonate B-obj
. O

Use B-acn
caffeine B-obj
citrate I-obj
routinely O
in O
preterm B-mod
babies B-obj
born O
at O
or O
before O
30 O
weeks O
, O
starting B-acn
it B-obj
as O
early O
as O
possible O
and O
ideally O
before O
3 O
days O
of O
age O
. O

Patients B-acr
with O
AIIRD B-obj
should O
receive B-acn
tetanus B-obj
toxoid I-obj
vaccination I-obj
in O
accordance O
to O
recommendations B-obj
for O
the O
general B-mod
population B-obj
. O

To O
induce B-acn
remission B-obj
in O
people B-acr
with O
a O
mild-to-moderate B-mod
first I-mod
presentation B-obj
or O
inflammatory B-mod
exacerbation B-obj
of O
proctosigmoiditis O
or O
left-sided B-mod
ulcerative B-obj
colitis I-obj
, O
offer B-acn
a O
topical B-mod
aminosalicylate B-obj
as O
first-line B-mod
treatment B-obj
. O

Consider B-acn
thoracic B-obj
radiotherapy I-obj
with O
prophylactic B-obj
cranial I-obj
irradiation I-obj
for O
people B-acr
with O
extensive-stage B-mod
disease B-obj
SCLC I-obj
. O

If O
remission B-obj
is O
not O
achieved B-mod
within O
4 O
weeks O
, O
consider B-acn
adding O
an O
oral B-mod
aminosalicylate B-obj
. O

Assess B-acn
thiopurine B-obj
methyltransferase I-obj
activity I-obj
before O
offering O
azathioprine B-obj
or O
mercaptopurine B-obj
. O

If O
the O
person B-acr
is O
with O
CKD B-obj
and O
hypertension B-obj
and O
an O
ACR B-obj
of O
30 B-mod
mg/mmol I-mod
or O
more B-mod
, O
offer B-acn
a O
low-cost B-mod
renin-angiotensin-aldosterone I-mod
system B-obj
antagonist I-obj
. O

Offer B-acn
people B-acr
who O
present B-acn
with O
superior B-mod
vena B-obj
cava I-obj
obstruction B-obj
chemotherapy I-obj
and O
radiotherapy B-obj
according O
to O
the O
stage B-obj
of O
disease B-obj
and O
performance B-mod
status B-obj
. O

If O
a O
person B-acr
is O
unable B-mod
to O
tolerate B-acn
ABPM B-obj
, O
HBPM B-obj
is O
a O
suitable B-mod
alternative I-mod
to O
confirm B-acn
the O
diagnosis B-obj
of O
hypertension B-obj
. O

Do O
not O
offer B-acn
a O
bisphosphonate B-obj
to O
pregnant B-mod
women B-acr
with O
primary B-mod
hyperparathyroidism B-obj
. O

Consider B-acn
dual B-mod
therapy B-obj
with O
ACE B-obj
inhibitor I-obj
and O
metformin B-obj
if O
the O
person B-acr
is O
aged O
under B-mod
80 B-obj
years I-obj
. O

If O
the O
treatment B-obj
target I-obj
is O
not O
achieved B-mod
with O
the O
first B-mod
csDMARD B-obj
strategy I-obj
, O
when O
poor B-mod
prognostic B-obj
factors I-obj
are O
present B-mod
, O
addition B-obj
of O
a O
bDMARD B-obj
or O
a O
tsDMARD B-obj
should O
be O
considered B-mod
. O

Disease B-obj
activity I-obj
should O
be O
controlled B-mod
optimally O
in O
order O
to O
lower B-acn
CVD B-obj
risk I-obj
in O
all O
patients B-acr
with O
RA B-obj
, O
AS B-obj
or O
PsA B-obj
. O

Sotalol B-obj
therapy I-obj
is O
not O
recommended B-mod
for O
patients B-acr
following B-acn
ACS B-obj
who O
do O
not O
have B-acn
sustained B-mod
ventricular B-obj
arrhythmias I-obj
or O
atrial B-obj
fibrillation I-obj
. O

Women B-acr
with O
platinum B-mod
sensitive I-mod
relapsed B-obj
ovarian I-obj
cancer I-obj
should O
be O
offered B-mod
treatment B-obj
with O
carboplatin B-obj
combined B-mod
with O
either O
paclitaxel B-obj
or O
pegylated B-obj
liposomal I-obj
doxorubicin I-obj
hydrochloride I-obj
. O

Hepatitis B-obj
A I-obj
and/or O
B B-obj
vaccination I-obj
is O
only O
recommended B-mod
in O
patients B-acr
with O
AIIRD B-obj
at O
risk O
. O

Acute B-mod
withdrawal B-obj
of O
beta-blockers B-obj
in O
the O
postoperative B-mod
period B-obj
is O
not O
recommended B-obj
. O

Consider B-acn
bisphosphonates B-obj
as O
adjuvant B-mod
therapy B-obj
for O
postmenopausal B-mod
women B-obj
with O
node-negative B-mod
invasive I-mod
breast B-obj
cancer I-obj
and O
a O
high O
risk O
of O
recurrence O
. O

Patients B-acr
with O
AF B-obj
who O
remain B-acn
severely O
symptomatic B-mod
despite O
adequate O
rate B-obj
control I-obj
should O
be O
considered B-mod
for O
rhythm B-obj
control I-obj
or O
for O
stricter O
rate B-obj
control I-obj
if O
their O
heart B-obj
rate I-obj
remains B-acn
80-110 O
bpm O
at O
rest O
. O

For O
patients B-acr
with O
HCV B-obj
genotype I-obj
1 I-obj
infection I-obj
and O
HIV B-obj
, O
who O
do O
not O
achieve B-acn
an O
EVR B-obj
, O
treatment B-obj
should O
be O
stopped B-mod
. O

If O
one O
TNF-inhibitor B-obj
therapy I-obj
has O
failed B-acn
, O
patients B-acr
may O
receive B-acn
another O
TNF-inhibitor B-obj
or O
an O
agent B-obj
with O
another O
mode B-obj
of O
action B-obj
. O

In O
patients B-acr
being O
considered B-mod
for O
active B-mod
therapy B-obj
, O
pleural B-mod
effusion B-obj
should O
be O
investigated B-mod
with O
pleural B-mod
aspiration B-obj
and/or O
pleural B-mod
biopsy B-obj
using O
image-guided B-mod
or O
thoracoscopic B-mod
biopsy B-obj
. O

In O
patients B-acr
with O
axial B-mod
SpA B-obj
without O
syndesmophytes B-obj
in O
the O
lumbar B-obj
spine I-obj
on O
conventional B-mod
radiography B-obj
, O
osteoporosis B-obj
should O
be O
assessed B-mod
by O
hip B-obj
DXA I-obj
and O
AP-spine B-obj
DXA I-obj
. O

If O
the O
treatment B-obj
target I-obj
is O
not O
achieved B-mod
with O
the O
first B-mod
csDMARD B-obj
strategy I-obj
, O
in O
the O
absence B-obj
of O
poor B-mod
prognostic B-obj
factors I-obj
, O
other O
csDMARDs B-obj
should O
be O
considered B-mod
. O

Patients B-acr
with O
HCV B-mod
associated I-mod
chronic B-obj
liver I-obj
failure I-obj
should O
be O
considered B-mod
for O
assessment B-obj
for O
liver B-obj
transplantation I-obj
. O

Fluoxetine B-obj
should O
be O
considered B-mod
for O
the O
treatment B-obj
of O
patients B-acr
with O
fibromyalgia B-obj
. O

Assess B-acn
the O
HER2 B-obj
status I-obj
of O
all O
invasive B-mod
breast B-obj
cancers I-obj
using B-acn
standardised B-mod
and O
quality-assured B-mod
techniques B-obj
, O
and O
report B-acn
the O
results B-obj
quantitatively B-mod
. O

Do O
not O
use B-acn
dexamethasone B-obj
with O
non-steroidal B-mod
anti-inflammatory I-mod
drugs B-obj
. O

If O
the O
person B-acr
is O
with O
stage B-obj
2 I-obj
diabetes I-obj
and O
symptomatically B-mod
hyperglycaemic I-mod
, O
offer B-acn
SGLT-2i B-obj
, O
pioglitazone B-obj
or O
ergocalciferol B-obj
. O

In O
patients B-acr
who O
have O
recovered B-acn
from O
an O
episode O
of O
sustained B-mod
ventricular B-obj
tachycardia I-obj
who O
are O
not O
candidates B-mod
for O
an O
ICD B-obj
, O
amiodarone B-obj
or O
sotalol B-obj
should O
be O
considered B-mod
. O

Perform B-acn
transthoracic B-obj
echocardiography I-obj
to O
exclude B-acn
important O
valve B-obj
disease I-obj
, O
assess B-acn
the O
systolic B-obj
function I-obj
of O
the O
ventricle B-obj
, O
and O
detect B-acn
intracardiac B-mod
shunts B-obj
. O

CVD B-obj
risk I-obj
prediction I-obj
models I-obj
should O
be O
adapted B-mod
for O
patients B-acr
with O
RA B-obj
by O
a O
1.5 B-obj
multiplication I-obj
factor I-obj
, O
if O
this B-acr
is O
not O
already O
included B-mod
in O
the O
model B-obj
. O

A O
regimen O
containing O
a O
platinum B-obj
agent I-obj
and O
etoposide B-obj
is O
recommended B-mod
for O
first B-mod
line I-mod
treatment B-obj
of O
patients B-acr
with O
SCLC B-obj
. O

Advise B-acn
pregnant B-mod
women B-acr
at O
high O
risk O
of O
pre-eclampsia O
to O
take B-acn
75-150 B-mod
mg I-mod
of O
aspirin B-obj
daily O
from O
12 O
weeks O
until O
the O
birth O
of O
the O
baby O
. O

Offer B-acn
contrast-enhanced B-mod
brain B-obj
CT I-obj
to O
people B-acr
with O
clinical B-mod
stage B-obj
2 I-obj
NSCLC I-obj
who O
are O
having B-acn
treatment B-obj
with O
curative B-mod
intent B-obj
. O

If O
HbA1c B-acr
rises B-acn
to O
48 B-mod
mmol/mol I-mod
( I-mod
6.5 I-mod
% I-mod
) I-mod
on O
lifestyle O
interventions O
, O
offer B-acn
metformin B-obj
and O
support B-acn
the O
person B-obj
to O
aim B-acn
for O
an O
HbA1c B-obj
level I-obj
of O
48 B-mod
mmol/mol I-mod
( I-mod
6.5 I-mod
% I-mod
) I-mod
. O

For O
people B-acr
who O
are O
at O
low B-mod
risk I-mod
of O
developing O
a O
diabetic B-mod
foot B-obj
problem I-obj
, O
continue B-acn
to O
carry O
out O
annual B-mod
foot B-obj
assessments I-obj
. O

If O
the O
diagnosis B-acn
is O
still O
unclear B-mod
, O
offer B-acn
CT B-obj
and O
EUS B-obj
with O
EUS-guided B-mod
tissue B-obj
sampling I-obj
. O

Consider B-acn
endocrine B-obj
therapy I-obj
after O
breast-conserving B-obj
surgery I-obj
for O
women B-acr
with O
ER-positive B-mod
DCIS B-obj
if O
radiotherapy B-obj
is O
not O
recommended B-mod
. O

Start B-acn
a O
trial B-obj
of O
a O
renin-angiotensin B-obj
system I-obj
blocking I-obj
drug I-obj
as O
first-line B-mod
therapy B-obj
for O
hypertension B-obj
in O
adults B-obj
with O
type B-obj
1 I-obj
diabetes I-obj
. O

Pregabalin B-obj
is O
recommended B-mod
for O
the O
treatment B-obj
of O
patients B-acr
with O
fibromyalgia B-obj
. O

Consider B-acn
second-line B-mod
palliative B-obj
chemotherapy I-obj
for O
people B-acr
with O
oesophago-gastric B-obj
cancer I-obj
. O

Do O
not O
offer B-acn
dedicated B-mod
brain B-obj
imaging I-obj
to O
people B-acr
with O
clinical B-mod
stage B-obj
1 I-obj
NSCLC I-obj
who O
have B-acn
no O
neurological B-obj
symptoms I-obj
and O
are O
having B-acn
treatment B-obj
with O
curative B-mod
intent B-obj
. O

Carbamazepine B-obj
should O
be O
considered B-mod
for O
the O
treatment B-obj
of O
patients B-acr
with O
neuropathic B-obj
pain I-obj
. O

All O
patients B-acr
with O
heart B-obj
failure I-obj
with O
reduced B-mod
ejection B-obj
fraction I-obj
, O
NYHA B-obj
class I-obj
2-4 I-obj
should O
be O
started B-mod
on O
beta-blocker B-obj
therapy I-obj
as O
soon O
as O
their O
condition B-obj
is O
stable B-mod
. O

If O
the O
clinic B-mod
blood B-obj
pressure I-obj
is O
140/90 B-mod
mmHg I-mod
or O
higher B-mod
, O
offer B-acn
ABPM B-obj
to O
confirm B-acn
the O
diagnosis B-obj
of O
hypertension B-obj
. O

The O
vaccination B-obj
status I-obj
should O
be O
assessed B-mod
in O
the O
initial B-mod
work-up B-obj
of O
patients B-acr
with O
AIIRD B-obj
. O

Offer B-acn
endoscopic B-mod
mucosal B-obj
resection I-obj
for O
staging O
to O
people B-acr
with O
suspected B-mod
T1 B-obj
oesophageal I-obj
cancer I-obj
. O

In O
surgery B-obj
for O
advanced B-mod
ovarian B-obj
cancer I-obj
, O
the O
aim O
should O
be O
to O
achieve B-acn
complete B-mod
cytoreduction B-obj
. O

Do O
not O
offer B-acn
prostaglandin B-obj
F2 I-obj
alpha I-obj
to O
women B-acr
with O
asthma B-obj
because O
of O
the O
risk O
of O
bronchospasm B-obj
. O

BCG B-obj
vaccination I-obj
is O
not O
recommended B-mod
in O
patients B-acr
with O
AIIRD B-obj
. O

Patients B-acr
and O
the O
patients' B-obj
treatment I-obj
teams I-obj
should O
receive B-acn
appropriate B-mod
, O
practical B-mod
advice B-obj
on O
how O
to O
manage B-acn
with O
GC-induced B-mod
hypothalamic-pituitary-adrenal B-obj
axis I-obj
suppression I-obj
. O

To O
induce B-acn
remission B-obj
in O
people B-acr
with O
a O
mild-to-moderate B-mod
first I-mod
presentation B-obj
or O
inflammatory B-mod
exacerbation B-obj
of O
proctitis B-obj
, O
offer B-acn
a O
topical B-mod
aminosalicylate B-obj
as O
first-line B-mod
treatment B-obj
. O

CVD B-obj
risk I-obj
assessment I-obj
is O
recommended B-mod
for O
all O
patients B-acr
with O
RA B-obj
, O
AS B-obj
or O
PsA B-obj
at O
least O
once O
every O
5 O
years O
and O
should O
be O
reconsidered B-mod
following B-acn
major B-mod
changes B-obj
in O
antirheumatic B-obj
therapy I-obj
. O

In O
peripheral B-mod
SpA B-obj
, O
if O
the O
clinical B-mod
scenario B-acr
requires B-acn
monitoring B-obj
of O
structural B-mod
damage B-obj
, O
then O
conventional B-mod
radiography B-obj
is O
recommended B-mod
. O

Inactivated B-mod
influenza B-obj
vaccination I-obj
should O
be O
strongly O
considered B-mod
for O
patients B-acr
with O
AIIRD B-obj
. O

Patients B-acr
with O
heart B-obj
failure I-obj
with O
reduced B-mod
ejection B-obj
fraction I-obj
, O
NYHA B-obj
class I-obj
2-4 I-obj
, O
who O
are O
intolerant B-mod
of O
angiotensin B-mod
converting I-mod
enzyme B-obj
inhibitors I-obj
should O
be O
given B-mod
an O
angiotensin B-obj
receptor I-obj
blocker I-obj
. O

If O
CT B-acr
shows B-acn
suspected B-mod
brain B-obj
metastases I-obj
, O
offer B-acn
contrast-enhanced B-mod
brain B-obj
MRI I-obj
. O

Offer B-acn
flexible B-mod
bronchoscopy B-obj
to O
people B-acr
with O
central B-mod
lesions B-obj
on O
CT O
if O
nodal B-obj
staging I-obj
does O
not O
influence B-acn
treatment B-obj
. O

Offer B-acn
PET-CT B-obj
, O
followed O
by O
EBUS-TBNA B-obj
and/or O
EUS-FNA B-obj
, O
to O
people B-acr
with O
suspected B-mod
lung B-obj
cancer I-obj
who O
have B-acn
enlarged B-mod
intrathoracic B-obj
lymph I-obj
nodes I-obj
and O
who O
could O
potentially O
have B-acn
treatment B-obj
with O
curative B-mod
intent B-obj
. O

Measure B-acn
N-terminal B-obj
pro-B-type I-obj
natriuretic I-obj
peptide I-obj
in O
people B-acr
with O
suspected B-mod
heart B-obj
failure I-obj
. O

Keep B-acn
the O
requirement B-obj
for O
continuing B-acn
GC B-obj
treatment I-obj
under O
constant B-mod
review B-obj
, O
and O
titrate B-obj
the O
dose B-obj
against O
therapeutic B-mod
response B-obj
, O
risk B-obj
of O
undertreatment B-obj
and O
development B-obj
of O
AEs B-obj
. O

Review B-acn
intravenous B-mod
antibiotics B-obj
by O
48 O
hours O
and O
consider B-acn
stepping B-acn
down O
to O
oral B-mod
antibiotics B-obj
where O
possible O
. O

For O
women B-acr
with O
a O
cerebrovascular B-obj
malformation I-obj
at O
low B-mod
risk B-obj
of O
intracranial B-obj
bleeding I-obj
, O
base B-acn
decisions B-obj
on O
the O
mode O
of O
birth O
on O
the O
woman's B-mod
preference B-obj
and O
obstetric B-obj
indications I-obj
. O

If O
SABR B-obj
is O
contraindicated B-mod
, O
offer B-acn
either O
conventional B-mod
or O
hyperfractionated B-mod
radiotherapy B-obj
. O

Offer B-acn
antihypertensive B-mod
drug B-obj
treatment I-obj
for O
an O
annual B-obj
vaccination I-obj
against O
influenza B-obj
. O

Short-term B-mod
GC B-obj
should O
be O
considered B-mod
when O
initiating B-acn
or O
changing B-acn
csDMARDs B-obj
, O
in O
different O
dose B-obj
regimens I-obj
and O
routes O
of O
administration O
, O
but O
should O
be O
tapered B-mod
as O
rapidly B-mod
as O
clinically B-mod
feasible I-mod
. O

Transmyocardial B-obj
laser I-obj
revascularisation I-obj
is O
not O
recommended B-mod
for O
the O
treatment B-obj
of O
stable B-mod
angina B-obj
. O

Patients B-acr
with O
stage B-obj
1 I-obj
and O
2 B-obj
NSCLC I-obj
should O
be O
considered B-mod
for O
curative B-mod
surgery B-obj
whenever O
possible O
. O

If O
the O
person B-acr
has B-acn
stage B-obj
2 I-obj
hypertension I-obj
, O
offer B-acn
antihypertensive B-mod
drug B-obj
treatment I-obj
. O

Antihypertensives B-obj
and O
statins B-obj
may O
be O
used B-mod
as O
in O
the O
general B-mod
population B-obj
. O

Do O
not O
use B-acn
synchronised B-mod
pressure-limited I-mod
ventilation B-obj
such O
as O
assist B-obj
control I-obj
, O
synchronised B-mod
intermittent I-mod
positive I-mod
pressure I-mod
ventilation B-obj
, O
patient-triggered B-mod
ventilation B-obj
, O
pressure B-mod
support I-mod
ventilation B-obj
or O
synchronised B-mod
time-cycled I-mod
pressure-limited I-mod
ventilation B-obj
. O

Patients B-acr
who O
are O
unfit B-mod
for O
combination B-obj
therapy I-obj
should O
be O
offered B-mod
single B-mod
agent I-mod
carboplatin B-obj
. O

Do O
not O
offer B-acn
ACE B-obj
inhibitor I-obj
therapy I-obj
if O
there O
is O
a O
clinical B-mod
suspicion B-obj
of O
haemodynamically O
significant O
valve B-obj
disease I-obj
until O
the O
valve B-obj
disease I-obj
has O
been O
assessed B-mod
by O
a O
specialist B-acr
. O

Patients B-acr
with O
mild B-mod
CHC B-obj
should O
be O
considered B-mod
for O
treatment B-obj
. O

In O
patients B-acr
with O
a O
contraindication B-obj
to O
MTX B-obj
, O
leflunomide B-obj
or O
sulfasalazine B-obj
should O
be O
considered B-mod
as O
part O
of O
the O
treatment B-obj
strategy I-obj
. O

Second B-mod
line I-mod
systemic B-obj
anticancer I-obj
therapy I-obj
with O
single B-obj
agent I-obj
docetaxel I-obj
or O
erlotinib B-obj
should O
be O
considered B-mod
for O
patients B-acr
with O
performance B-obj
status I-obj
0-2 I-obj
recurrent I-obj
NSCLC I-obj
who O
have O
been O
previously O
treated B-mod
with O
first B-mod
line I-mod
SACT B-obj
for O
advanced B-mod
disease B-obj
. O

TC B-obj
and O
HDLc B-obj
should O
be O
used B-mod
in O
CVD B-obj
risk I-obj
assessment I-obj
in O
RA B-obj
, O
AS B-obj
and O
PsA B-obj
and O
lipids B-obj
should O
ideally O
be O
measured B-mod
when O
disease B-obj
activity I-obj
is O
stable B-mod
or O
in O
remission B-obj
. O

Measure B-acn
parathyroid B-obj
hormone I-obj
for O
people B-acr
whose O
albumin-adjusted B-obj
serum I-obj
calcium I-obj
level I-obj
is O
either O
2.6 O
mmol/litre O
or O
above O
on O
at O
least O
2 O
separate O
occasions O
or O
2.5 O
mmol/litre O
or O
above O
on O
at O
least O
2 O
separate O
occasions O
and O
primary B-mod
hyperparathyroidism B-obj
is O
suspected B-mod
. O

Consider B-acn
azathioprine B-obj
or O
mercaptopurine B-obj
at O
a O
lower B-mod
dose B-obj
if O
TPMT B-obj
activity I-obj
is O
below B-mod
normal I-mod
but O
not O
deficient B-mod
. O

Consider B-acn
cinacalcet B-obj
for O
people B-acr
with O
primary B-mod
hyperparathyroidism B-obj
if O
surgery B-obj
has O
been O
unsuccessful B-mod
, O
is O
unsuitable B-mod
or O
has O
been O
declined B-mod
, O
and O
if O
their O
albumin-adjusted B-obj
serum I-obj
calcium I-obj
level I-obj
is O
either O
: O
2.85 B-mod
mmol/litre I-mod
or O
above O
with O
symptoms O
of O
hypercalcaemia O
or O
3 B-mod
mmol/litre I-mod
or O
above O
with O
or O
without O
symptoms O
of O
hypercalcaemia O
. O

If O
performed O
, O
it B-acr
should O
not O
be O
repeated B-acn
more O
frequently O
than O
every O
second O
year O
. O

If O
liver B-mod
function I-mod
blood B-obj
tests I-obj
are O
abnormal B-mod
, O
perform B-acn
a O
liver B-obj
ultrasound I-obj
scan I-obj
and O
consider B-acn
ursodeoxycholic B-obj
acid I-obj
treatment I-obj
. O

Offer B-acn
staging B-obj
laparoscopy I-obj
to O
all O
people B-acr
with O
potentially O
curable B-mod
gastric B-obj
cancer I-obj
. O

In O
patients B-acr
with O
PsA B-obj
, O
NSAIDs B-obj
may O
be O
used B-mod
to O
relieve B-acn
musculoskeletal B-mod
signs B-obj
and O
symptoms B-obj
. O

Long B-mod
term I-mod
beta-blockers B-obj
are O
recommended B-mod
for O
routine B-mod
use B-obj
in O
patients B-acr
following B-acn
ACS B-obj
without O
contraindications O
. O

Ensure B-acn
that O
people B-acr
with O
disabling B-mod
ischaemic B-obj
stroke I-obj
who O
are O
in O
atrial B-mod
fibrillation B-obj
are O
treated O
with O
aspirin B-obj
300 O
mg O
for O
the O
first O
2 O
weeks O
before O
anticoagulation B-obj
treatment I-obj
is O
considered B-mod
. O

All O
patients B-acr
should O
have B-acn
appropriate B-mod
monitoring B-obj
for O
clinically B-mod
significant I-mod
AEs B-obj
. O

If O
the O
person B-acr
is O
aged O
under B-mod
80 B-obj
years I-obj
with O
stage B-obj
1 I-obj
hypertension I-obj
and O
has B-acn
10 B-mod
year I-mod
cardiovascular B-obj
risk I-obj
, O
offer B-acn
antihypertensive B-mod
drug B-obj
treatment I-obj
. O

Review B-acn
antibiotic B-obj
treatment I-obj
after O
14 O
days O
and O
either O
stop B-acn
the O
antibiotic B-obj
or O
continue B-acn
for O
a O
further O
14 O
days O
if O
needed O
, O
based B-acn
on O
an O
assessment B-mod
of O
the O
person's O
history B-obj
, O
symptoms B-obj
, O
clinical B-mod
examination B-obj
, O
urine B-obj
and O
blood B-obj
tests I-obj
. O

Measure B-acn
serum B-obj
calcium I-obj
for O
adults B-obj
with O
ureteric B-obj
or O
renal B-obj
stones I-obj
. O

Advise B-acn
pregnant B-mod
women B-acr
with O
more O
than O
1 O
moderate O
risk O
factor O
for O
pre-eclampsia O
to O
take B-acn
75-150 B-mod
mg I-mod
of O
aspirin B-obj
daily O
from O
12 O
weeks O
until O
the O
birth O
of O
the O
baby O
. O

Optimised B-mod
antidepressant B-obj
therapy I-obj
should O
be O
considered B-mod
for O
the O
treatment B-obj
of O
patients B-acr
with O
chronic B-mod
pain B-obj
with O
moderate B-mod
depression B-obj
. O

In O
patients B-acr
who O
cannot O
use B-acn
csDMARDs B-obj
as O
comedication B-obj
, O
IL-6 B-obj
pathway I-obj
inhibitors I-obj
and O
tsDMARDs B-obj
may O
have B-acn
some O
advantages B-obj
compared B-mod
with O
other O
bDMARDs B-obj
. O

If O
the O
person B-acr
is O
symptomatically O
hyperglycaemic B-mod
, O
offer B-acn
antispasmodics B-obj
to O
have B-acn
HbA1c B-obj
level I-obj
of O
53 B-mod
mmol/mol I-mod
( I-mod
7.5 I-mod
% I-mod
) I-mod
. O

